{"url":"https://lda.senate.gov/api/v1/filings/2cc22c73-87bb-4ff7-9b05-0845d55bafd2/","filing_uuid":"2cc22c73-87bb-4ff7-9b05-0845d55bafd2","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2014,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/2cc22c73-87bb-4ff7-9b05-0845d55bafd2/print/","filing_document_content_type":"text/html","income":"7500.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus, President","dt_posted":"2015-01-20T15:19:01.683000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.senate.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-07-20T15:27:02.288049-04:00"},"client":{"id":176459,"url":"https://lda.senate.gov/api/v1/clients/176459/","client_id":416,"name":"ALLERGAN PLC","general_description":"Allergan is a diversified global pharmaceutical company","client_government_entity":false,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-09-16"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Development of policies to advance the antimicrobial research and development environment. Support of H.R.4187 - \"DISARM Act of 2014.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59333,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}